Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
2011
In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was associated with a trend toward a reduction in the decline in lung function, with fewer acute exacerbations and preserved quality of life. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT00514683.)
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
22
References
758
Citations
NaN
KQI